"The primary endpoint was radiographic progression-free survival. Median rPFS in Pluvicto-treated patients was 12.0 months, versus 5.6 months in the control group, giving a hazard ratio of 0.43, according to the leaked abstract."
"More details will be needed, and safety will be something to look at closely when full PSMAfore data are presented at ESMO on Monday. Doctors are particularly concerned about bone marrow toxicity."
Sad to say that Pluvicto did not work for me. After 3 cycles, my MO advised me to stop it and go back to chemo which had initially brought my PSA down over 50%. I hope others have better luck with it.
Here is a report of the presentation at ESMO 2023:
urotoday.com/conference-hig...
This is a discussion of this presentation:
Every time I see the word Pluvicto here on H.U. it's always associated with negative comments. Just my opinion/observances.
Good Luck, Good Health and Good Humor.
j-o-h-n Monday 10/23/2023 11:12 PM DST
Seems like the data does show some positive results, but long term effects not clearly understood. Bone marrow is something to watch out for. This is of concern for me. I've been on Lu77 treatment and short term after infusion platelets (formed in marrow) drop, but then bounce back. I would imagine that long-term effects would at least in part be related to the physical health of a patient I'm doing my best for the latter, and keeping an eye on the former after 4/6 treatments. Results from PSMAddition study I'm on will hopefully provide more data and information on this.
Duration of ADT
Metformin: Preliminary Results of Trial in Advanced Prostate Cancer (MANSMED)
Testing for BRCA Mutations.
Tolerability and treatment response to darolutamide in patients with nmCRPC in the phase III ARAMIS trial
